Fidelity International’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$38.3M Buy
242,331
+170,603
+238% +$23.1M 0.03% 391
2026
Q1
$9.16M Sell
71,728
-135,849
-65% -$17M 0.01% 600
2025
Q4
$25.4M Buy
207,577
+198,386
+2,158% +$22.7M 0.02% 445
2025
Q3
$921K Buy
+9,191
New +$828K ﹤0.01% 786
2024
Q4
Sell
-166,962
Closed -$16.5M 985
2024
Q3
$16.5M Buy
166,962
+83,428
+100% +$8.2M 0.02% 483
2024
Q2
$7.74M Buy
83,534
+32,102
+62% +$2.88M 0.01% 554
2024
Q1
$4.9M Sell
51,432
-110,257
-68% -$10.2M ﹤0.01% 593
2023
Q4
$14.5M Buy
+161,689
New +$12M 0.02% 457

Other funds holding XBI

Fidelity International's XBI Position: Q2 2026 in Review

Fidelity International increased its State Street SPDR S&P Biotech ETF (XBI) stake by 238% in Q2 2026, buying an estimated $23.1M and bringing the position to 242,331 shares worth $38.3M. The position accounts for 0.03% of the portfolio, ranked #391.

Fidelity International first reported a position in XBI in Q4 2023 and has held it in 8 quarters since. 842 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Fidelity International held 242,331 shares of State Street SPDR S&P Biotech ETF worth $38.3M as of Q2 2026.
  • Fidelity International bought 170,603 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $23.1M.
  • State Street SPDR S&P Biotech ETF made up 0.03% of Fidelity International's portfolio in Q2 2026, its #391 holding.
  • Fidelity International first reported a position in State Street SPDR S&P Biotech ETF in Q4 2023 and has held it in 8 quarters since.
  • 842 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Fidelity International's 13F filing for Q2 2026, filed 13 Aug 2026.